{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:41:53Z","timestamp":1789875713496,"version":"4.0.1"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/md.0000000000006698","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T16:31:42Z","timestamp":1496248302000},"page":"e6698","source":"Crossref","is-referenced-by-count":58,"title":["Efficacy of antidepressive medication for depression in Parkinson disease"],"prefix":"10.1097","volume":"96","author":[{"given":"Chuanjun","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210309","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jns.2014.10.014","article-title":"Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?","volume":"347","author":"Kataoka","year":"2014","journal-title":"J Neurol Sci"},{"key":"R2-2-20210309","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.4103\/0366-6999.159349","article-title":"Dopamine agonists exert Nurr1-inducing effect in peripheral blood mononuclear cells of patients with Parkinson's disease","volume":"128","author":"Zhang","year":"2015","journal-title":"Chin Med J (Engl"},{"key":"R3-2-20210309","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pnpbp.2004.11.023","article-title":"Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports","volume":"29","author":"Takahashi","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R4-2-20210309","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2298\/VSP111114028K","article-title":"Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine\/norfluoxetine","volume":"69","author":"Kostic","year":"2012","journal-title":"Vojnosanit Pregl"},{"key":"R5-2-20210309","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.neuropsych.11090210","article-title":"Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?","volume":"24","author":"Zahodne","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R6-2-20210309","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.20723","article-title":"Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS\/NIMH Work Group","volume":"21","author":"Marsh","year":"2006","journal-title":"Mov Disord"},{"key":"R7-2-20210309","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients","volume":"22","author":"Barone","year":"2015","journal-title":"Eur J Neurol"},{"key":"R8-2-20210309","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"key":"R9-2-20210309","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"R10-2-20210309","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"R11-2-20210309","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","article-title":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias","volume":"39","author":"Knobloch","year":"2011","journal-title":"J Craniomaxillofac Surg"},{"key":"R12-2-20210309","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R13-2-20210309","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","article-title":"DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group","volume":"46","author":"Group","year":"1989","journal-title":"Arch Neurol"},{"key":"R14-2-20210309","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF02229158","article-title":"A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.","volume":"13","author":"Group","year":"1992","journal-title":"Ital J Neurol Sci"},{"key":"R15-2-20210309","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/mds.870080508","article-title":"Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial","volume":"8","author":"Allain","year":"1993","journal-title":"Mov Disord"},{"key":"R16-2-20210309","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ana.410330404","article-title":"A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group","volume":"33","author":"Group","year":"1993","journal-title":"Ann Neurol"},{"key":"R17-2-20210309","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archneur.1994.00540160036006","article-title":"A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group","volume":"51","author":"Group","year":"1994","journal-title":"Arch Neurol"},{"key":"R18-2-20210309","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00002826-199508000-00007","article-title":"Effects of selegiline (deprenyl) on cognition in early Parkinson's disease","volume":"18","author":"Dalrymple-Alford","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"R19-2-20210309","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.410400116","article-title":"Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group","volume":"40","author":"Group","year":"1996","journal-title":"Ann Neurol"},{"key":"R20-2-20210309","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.","volume":"278","author":"Group","year":"1997","journal-title":"JAMA"},{"key":"R21-2-20210309","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mds.870120207","article-title":"The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian\u2013Danish 5-year study. Norwegian\u2013Danish Study Group","volume":"12","author":"Larsen","year":"1997","journal-title":"Mov Disord"},{"key":"R22-2-20210309","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08039489850139049","article-title":"Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial","volume":"52","author":"Wermuth","year":"1998","journal-title":"Nordic J Psychiatry"},{"key":"R23-2-20210309","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1468-1331.1999.650539.x","article-title":"Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian\u2013Danish Study Group","volume":"6","author":"Larsen","year":"1999","journal-title":"Eur J Neurol"},{"key":"R24-2-20210309","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-2-20210309","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R26-2-20210309","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","article-title":"Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study","volume":"72","author":"Pogarell","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R27-2-20210309","first-page":"1010","article-title":"[A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease]","volume":"35","author":"Serrano-Duenas","year":"2002","journal-title":"Rev Neurol"},{"key":"R28-2-20210309","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"key":"R29-2-20210309","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R30-2-20210309","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/mds.10538","article-title":"3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor","volume":"18","author":"Navan","year":"2003","journal-title":"Mov Disord"},{"key":"R31-2-20210309","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/mds.10359","article-title":"Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study","volume":"18","author":"Ziegler","year":"2003","journal-title":"Mov Disord"},{"key":"R32-2-20210309","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20145","article-title":"Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients","volume":"19","author":"Stern","year":"2004","journal-title":"Mov Disord"},{"key":"R33-2-20210309","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial","volume":"20","author":"Moller","year":"2005","journal-title":"Mov Disord"},{"key":"R34-2-20210309","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mds.20895","article-title":"Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life","volume":"21","author":"Antonini","year":"2006","journal-title":"Mov Disord"},{"key":"R35-2-20210309","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"R36-2-20210309","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4088\/JCP.v67n0905","article-title":"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial","volume":"67","author":"Feiger","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R37-2-20210309","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"R38-2-20210309","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"R39-2-20210309","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"R40-2-20210309","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Group","year":"2009","journal-title":"Arch Neurol"},{"key":"R41-2-20210309","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.22948","article-title":"Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease","volume":"25","author":"Bronzova","year":"2010","journal-title":"Mov Disord"},{"key":"R42-2-20210309","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.parkreldis.2010.12.003","article-title":"Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial","volume":"17","author":"Ondo","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"R43-2-20210309","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.23590","article-title":"Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials","volume":"26","author":"Sampaio","year":"2011","journal-title":"Mov Disord"},{"key":"R44-2-20210309","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov Disord"},{"key":"R45-2-20210309","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.parkreldis.2011.12.006","article-title":"Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial","volume":"18","author":"Rascol","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"R46-2-20210309","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"key":"R47-2-20210309","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.parkreldis.2013.03.003","article-title":"Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease \u2013 a randomized study","volume":"19","author":"Rios Romenets","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"R48-2-20210309","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.parkreldis.2013.07.009","article-title":"The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study","volume":"19","author":"Zhang","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"R49-2-20210309","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.25877","article-title":"Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease","volume":"29","author":"Hauser","year":"2014","journal-title":"Mov Disord"},{"key":"R50-2-20210309","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00415-014-7427-3","article-title":"Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"261","author":"Nomoto","year":"2014","journal-title":"J Neurol"},{"key":"R51-2-20210309","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ene.12757","article-title":"Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms \u2013 results of a double-blind, randomized, placebo-controlled trial","volume":"22","author":"Antonini","year":"2015","journal-title":"Eur J Neurol"},{"key":"R52-2-20210309","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jcph.678","article-title":"A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease-associated chronic pain","volume":"56","author":"Rascol","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R53-2-20210309","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov Disord"},{"key":"R54-2-20210309","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.expneurol.2015.02.005","article-title":"Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system","volume":"266","author":"Paumier","year":"2015","journal-title":"Exp Neurol"},{"key":"R55-2-20210309","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/mds.24978","article-title":"Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease","volume":"27","author":"Paumier","year":"2012","journal-title":"Mov Disord"},{"key":"R56-2-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.017","article-title":"Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats","volume":"77","author":"Conti","year":"2014","journal-title":"Neuropharmacology"},{"key":"R57-2-20210309","doi-asserted-by":"crossref","first-page":"e76651","DOI":"10.1371\/journal.pone.0076651","article-title":"Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"R58-2-20210309","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/00207450701239418","article-title":"The effects of antidepressants in Parkinson's disease: a meta-analysis","volume":"118","author":"Frisina","year":"2008","journal-title":"Int J Neurosci"},{"key":"R59-2-20210309","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2377-10-49","article-title":"Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Skapinakis","year":"2010","journal-title":"BMC Neurol"},{"key":"R60-2-20210309","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.parkreldis.2015.04.018","article-title":"Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis","volume":"21","author":"Bomasang-Layno","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"R61-2-20210309","doi-asserted-by":"crossref","first-page":"e79510","DOI":"10.1371\/journal.pone.0079510","article-title":"A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease","volume":"8","author":"Troeung","year":"2013","journal-title":"PLoS One"},{"key":"R62-2-20210309","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881113478282","article-title":"Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis","volume":"27","author":"Rocha","year":"2013","journal-title":"J Psychopharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:48:13Z","timestamp":1620960493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201706020-00002"}},"subtitle":["a network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":62,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006698","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}